Functional impact of sequelae in drug-susceptible and multidrug-resistant tuberculosis
Muñoz-Torrico M, Cid-Juárez S, Gochicoa-Rangel L, Torre-Bouscolet L, Salazar-Lezama MA, Villarreal-Velarde H, Pérez-Padilla R, Visca D, et al. (14 authors)
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2020-07
Abstract
BACKGROUND: Evidence on the impact of tuberculosis (TB) treatment on lung function is scarce. The aim of this study was to evaluate post-treatment sequelae in drug-susceptible and drug-resistant-TB (DR-TB) cases in Mexico and Italy. METHODS: At the end of TB treatment the patients underwent complete clinical assessment, functional evaluation of respiratory mechanics, gas exchange and a 6-minute walking test. Treatment regimens (and definitions) recommended by the World Health Organization were used throughout. RESULTS: Of 61 patients, 65.6% had functional impairment, with obstruction in 24/61 patients (39.4%), and 78% with no bronchodilator response. These effects were more prevalent among DR-TB cases (forced expiratory volume in 1 s/forced vital capacity [FEV 1 /FVC] P = 0.075). DR-TB patients showed moderately severe (FEV 1 1 P = 0.008). Pre- and post-bronchodilator FEV 1 and FEV 1 /FVC (% of predicted) were significantly lower among DR-TB cases. Plethysmography abnormalities (restriction, hyperinflation and/or air trapping) were more frequent among DR-TB cases ( P = 0.001), along with abnormal carbon monoxide diffusing capacity (DLCO) ( P = 0.003). CONCLUSION: The majority of TB patients suffer the consequences of post-treatment sequelae (of differing levels), which compromise quality of life, exercise tolerance and long-term prognosis. It is therefore important that lung function is comprehensively evaluated post-treatment to identify patient needs for future medication and pulmonary rehabilitation.
MeSH terms
- Lung
- Humans
- Tuberculosis, Multidrug-Resistant
- Pulmonary Disease, Chronic Obstructive
- Pharmaceutical Preparations
- Vital Capacity
- Forced Expiratory Volume
- Quality of Life
- Mexico
- Italy